Ocugen Files 8-K: Routine Update
Ticker: OCGN · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Ocugen filed an 8-K, mostly routine stuff, check exhibits for details.
AI Summary
Ocugen, Inc. filed an 8-K on August 5, 2024, reporting other events and financial statements. The filing does not contain specific details about new material events, acquisitions, or financial results, but rather serves as a routine update and filing of exhibits.
Why It Matters
This 8-K filing indicates Ocugen is meeting its regulatory reporting obligations. Investors should review the exhibits for any specific disclosures that may have been filed.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- August 5, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 11 Great Valley Parkway Malvern, Pennsylvania 19355 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Ocugen, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 5, 2024.
When was this 8-K report filed by Ocugen, Inc.?
This 8-K report was filed on August 5, 2024.
In which state is Ocugen, Inc. incorporated?
Ocugen, Inc. is incorporated in Delaware.
What are the principal executive offices of Ocugen, Inc.?
The principal executive offices of Ocugen, Inc. are located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
Does this filing indicate any specific new material events or financial results?
This filing indicates 'Other Events' and the filing of 'Financial Statements and Exhibits' but does not specify any new material events or detailed financial results within the provided text.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-05 07:18:41
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm2420843d1_8k.htm (8-K) — 26KB
- tm2420843d1_ex99-1.htm (EX-99.1) — 15KB
- tm2420843d1_ex99-1img001.jpg (GRAPHIC) — 113KB
- tm2420843d1_ex99-1img002.jpg (GRAPHIC) — 150KB
- tm2420843d1_ex99-1img003.jpg (GRAPHIC) — 136KB
- tm2420843d1_ex99-1img004.jpg (GRAPHIC) — 149KB
- tm2420843d1_ex99-1img005.jpg (GRAPHIC) — 155KB
- tm2420843d1_ex99-1img006.jpg (GRAPHIC) — 41KB
- 0001104659-24-085603.txt ( ) — 1241KB
- ocgn-20240805.xsd (EX-101.SCH) — 3KB
- ocgn-20240805_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240805_pre.xml (EX-101.PRE) — 22KB
- tm2420843d1_8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events. On August 5, 2024, Ocugen, Inc. issued a press release announcing that it has received notification from the U.S. Food and Drug Administration to begin its expanded access program for the treatment of adult patients, aged 18 and older, with retinitis pigmentosa with OCU400. A copy of the press releases is filed as Exhibits 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release, dated August 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 5, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder